12:00 AM
 | 
Apr 08, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Lymphoseek tilmanocept: Additional Phase III data

Top-line data from the open-label, U.S. Phase III NEO3-06 trial in over 80 patients with SCCHN showed that preoperative imaging with a single injection of Lymphoseek met the primary endpoint of accurately identifying sentinel lymph nodes as compared to the removal of all lymph nodes during multiple level nodal dissection surgery of the head and neck. Specifically, of the 39 patients determined to have pathology-positive lymph nodes, Lymphoseek accurately identified 38 sentinel...

Read the full 337 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >